Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Kalbitor
Ecallantide is a recombinant protein drug used to treat acute attacks of hereditary angioedema (HAE). It works by inhibiting kallikrein, a key enzyme in the inflammatory cascade that leads to the swelling characteristic of HAE. It belongs to the class of serine protease inhibitors and is administered subcutaneously.
For the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Outcome:
Increased risk of angioedema
Mechanism:
Both drugs affect the same pathway.
Outcome:
Reduced efficacy of ecallantide
Mechanism:
NSAIDs may exacerbate HAE symptoms.
Outcome:
Potential for reduced absorption of ecallantide
Mechanism:
Changes in stomach pH can affect drug absorption.
Most likely new formulation: Extended-release subcutaneous formulation (Year: 2026, 80% confidence)
Based on current usage patterns and emerging therapies, there is a 70% likelihood that ecallantide will maintain its current market share for the next 5 years.
Kallikrein Inhibitor, Serine Protease Inhibitor
Recombinant Protein